537 completed. 537 Phase 1, 115 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 537 | Completed 537 |
| Phase 2 | 115 | Completed 115 |
Follow Arthritis: new trials by email Literature Review of Arthritis trials Research Report on Arthritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-Drug Interaction Study of ABP-671 in Gout Patients ABP-671 plus allopurinol - Gout Chronic, Gout | Phase 1 | Completed | Atom Therapeutics Co., Ltd | 22 | 2026-01-23 | 2026-11-02 |
| The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy Subjects SHR-3045 Injection, SHR-3045 Placebo Injection - Rheumatoid Arthritis (RA) | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 16 | 2025-10-08 | 2026-06-11 |
| A Phase 1/2a Study to Evaluate Single Intraarticular Injections of 3 Dose Levels of SYN321 and Placebo in Patients With Symptomatic Knee Osteoarthritis SYN321, Placebo - Osteoarthritis of Knee | Phase 1 / Phase 2 | Completed | Synartro AB | 35 | 2025-08-19 | 2026-03-06 |
| Efficacy of Topical Insulin Gel as a Coupling Medium in Phonophoresis-Assisted Physiotherapy vs Liposomal Insulin in Management of Joint Inflammation Insulin, nano-insulin gel, phonophoresis and ultasound - Joint Inflammation | Phase 1 | Completed | Deraya University | 60 | 2025-07-01 | 2026-08-27 |
| EF-M2 (Immutalon) Multiple Ascending Dose Study in Moderate-to-Severe Rheumatoid Arthritis EF-M2 - Rheumatoid Arthritis | Phase 1 / Phase 2 | Completed | S.LAB (SOLOWAYS) | 48 | 2025-06-03 | 2026-01-16 |
| A Phase 1/2a to Evaluate the Safety and Efficacy of Adipose Tissue Allograft (BRC-OA) in Patients With Osteoarthritis of the Knee Cryopreserved Devitalized Adipose Tissue Allograft, Normal Saline (Placebo) - Osteoarthritis of Knee | Phase 1 / Phase 2 | Completed | Britecyte | 46 | 2025-05-05 | 2026-09-08 |
| A Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects SHR-3045 Injection, SHR-3045 Placebo Injection - Rheumatoid Arthritis | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 40 | 2025-04-08 | 2026-06-05 |
| Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain PIPE-791, Placebo - Chronic Osteoarthritis Pain, Chronic Low Back Pain | Phase 1 | Completed | Contineum Therapeutics | 43 | 2025-02-04 | 2026-03-18 |
| A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968 LEO 158968 - Joint Pain, Gout Flares | Phase 1 | Completed | LEO Pharma | 6 | 2025-01-07 | 2026-05-12 |
| Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetic, and Food Effects of ARD-885 Film-coated Tablets in Healthy Chinese Subjects and Patients With Rheumatoid Arthritis ARD-885 Tablets, ARD-885 Placebo Tablet - Rheumatoid Arthritis (RA) | Phase 1 | Completed | Artivila (Shenzhen) Innovation Center, Ltd | 94 | 2024-12-16 | 2025-12-05 |
| A First-in-human Study to Investigate Safety and Tolerability of SAR446959 in Participants With Osteoarthritis of the Knee SAR446959, Placebo - Osteoarthritis | Phase 1 | Completed | Sanofi | 32 | 2024-11-20 | 2026-01-12 |
| Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects Abatacept - Rheumatoid Arthritis (RA | Phase 1 | Completed | Kashiv BioSciences, LLC | 300 | 2024-07-04 | 2026-06-12 |
| A Bioequivalence Study of Two Different Dosage Form of Genakumab Genakumab Injection (T, Solution for injection), Genakumab for Injection (R, Powder for solution for injection) - Gouty Arthritis (GA) | Phase 1 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 178 | 2024-06-24 | 2025-02-11 |
| Evaluation of CYT-108, A Recombinant Protease Inhibitor, for Treatment of Mild To Moderate Primary Osteoarthritis Of The Knee CYT-108, a recombinant protease inhibitor, Phosphate Buffered Saline (PBS) - Osteoarthritis, Knee, Osteoarthritis | Phase 1 | Completed | Cytonics Corporation | 19 | 2024-06-01 | 2025-12-26 |
| Umbilical Cord Mesenchymal Stem Cell Secretome in Patients With Sjogren's Syndrome Umbilical cord mesenchymal stem cell-derived secretome, Placebo (0.9% sodium chloride) - Sjogren's Syndrome | Phase 1 / Phase 2 | Completed | Universitas Sebelas Maret Hospital | 29 | 2024-05-01 | 2026-11-02 |
| Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout Rituximab - Tophaceous Gout | Phase 1 | Completed | University of California, Los Angeles | 2 | 2024-04-10 | 2025-11-20 |
| A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor) dose-5 group, dose-1 group, dose-2 group - Gout Arthritis | Phase 1 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 30 | 2024-03-05 | 2024-03-22 |
| Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants OD-07656 - Inflammatory Bowel Diseases, Blau Syndrome | Phase 1 | Completed | Odyssey Therapeutics, Inc. | 101 | 2024-02-12 | 2025-02-21 |
| Study of Intra-articular Allocetra in Knee Osteoarthritis Allocetra, Placebo - Osteoarthritis, Knee | Phase 1 / Phase 2 | Completed | Enlivex Therapeutics Ltd. | 134 | 2024-01-26 | 2026-11-04 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers ABP-745, Placebo - Gout, Acute Gout Flare | Phase 1 | Completed | Atom Therapeutics Co., Ltd | 90 | 2024-01-23 | 2025-08-17 |
Showing 20 of 537. Sign in to see all of them.
Arthritis, Rheumatoid (252) · Osteoarthritis (113) · Osteoarthritis, Knee (96) · Gout (45) · Hyperuricemia (22) · Inflammation (19) · Arthritis, Psoriatic (18) · Sjogren's Syndrome (15) · Arthritis, Juvenile (13) · Lupus Erythematosus, Systemic (12) · Pain (11) · Spondylitis, Ankylosing (10) · Autoimmune Diseases (9) · Joint Diseases (8)
Musculoskeletal Diseases (530) · Joint Diseases (529) · Rheumatic Diseases (497) · Skin and Connective Tissue Diseases (296) · Connective Tissue Diseases (283) · Immune System Diseases (279) · Autoimmune Diseases (273) · Pathological Conditions, Signs and Symptoms (70) · Osteoarthritis (67) · Nutritional and Metabolic Diseases (53) · Metabolic Diseases (51) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (49) · Genetic Diseases, Inborn (49) · Crystal Arthropathies (47)
Methotrexate (20) · Naproxen (13) · tocilizumab (11) · Rituximab (9) · sarilumab (9) · Abatacept (8) · tofacitinib (8) · Midazolam (7) · fostamatinib (7) · Saline Solution (6) · ruzinurad (6) · verinurad (6) · Hyaluronic Acid (5) · Infliximab (5) · Allopurinol (4)
Pfizer (23) · Bristol-Myers Squibb (21) · AstraZeneca (18) · GlaxoSmithKline (11) · Sanofi (11) · Eli Lilly and Company (9) · Amgen (8) · Ardea Biosciences, Inc. (8) · Jiangsu HengRui Medicine Co., Ltd. (8) · Hoffmann-La Roche (7) · LG Chem (7) · Novo Nordisk A/S (7) · Regeneron Pharmaceuticals (7) · Mayo Clinic (6) · Novartis Pharmaceuticals (6)
United States (223) · Germany (49) · China (41) · United Kingdom (36) · South Korea (31) · Australia (30) · Spain (24) · Canada (22) · Netherlands (22) · Poland (19) · France (15) · Russia (15) · Belgium (14) · Japan (14) · Hungary (13)
Hamid Gourabi, PhD (4) · J. Hall, MD (4) · Nasser Aghdami, MD,PhD (4) · Alison Heald, MD (3)
PMID 26058927, PMID 20175977, PMID 21518322, PMID 25749867, PMID 25822648, PMID 28143815, PMID 29776017, PMID 32453485, PMID 32816215, PMID 33127856, PMID 33506875, PMID 34870800, PMID 35022448, PMID 36526796, PMID 36600185, PMID 36601090, PMID 36931693, PMID 38258274, PMID 39454617, PMID 10415784, PMID 12086165, PMID 17065354, PMID 17216685, PMID 17425783, PMID 18163497, PMID 18279523, PMID 18468955, PMID 18523506, PMID 18534016, PMID 18759293, PMID 18759314, PMID 18986773, PMID 19187557, PMID 19208097, PMID 19273451, PMID 19587341, PMID 19747581, PMID 19857081, PMID 20131246, PMID 20231202, PMID 20360503, PMID 20565725, PMID 20618964, PMID 20926833, PMID 20932341, PMID 20934693, PMID 21300401, PMID 21613310, PMID 22169051, PMID 22225620
2015 (10), 2017 (8), 2009 (7), 2008 (6), 2016 (3), 2018 (3), 2023 (2), 2014 (1), 2019 (1), K23AT001879 (1), R01AR056702 (1), R41AR051232 (1)